Contrast induced nephropathy risk factors
|
Contrast Induced Nephropathy Microchapters |
|
Differentiating Contrast induced nephropathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Contrast induced nephropathy risk factors On the Web |
|
American Roentgen Ray Society Images of Contrast induced nephropathy risk factors |
|
Directions to Hospitals Treating Contrast induced nephropathy |
|
Risk calculators and risk factors for Contrast induced nephropathy risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Overview
Many factors have been associated with an increased risk of contrast-induced nephropathy. Pre-existing renal insufficiency, pre-existing diabetes, age, volume of CM, and reduced intravascular volume are an example for these risk factor.[1][2] The total risk rises as the number of risk factors increase, it has been recommended that every known risk factor should be analyzed, to properly evaluate a total cumulative risk of developing contrast-induced nephropathy. A clinical prediction rule is available to estimate probability of nephropathy (increase ≥25% and/or ≥0.5 mg/dl in serum creatinine at 48 h)[3]
Risk Factors
Pre-existing renal disease
Pre-existing renal disease with an elevated level of serum creatinine considered to be the most crucial risk factor in the development of CIN. The incidence of CIN in patients with underlying chronic kidney disease is extremely high, ranging from 14.8 to 55%[4] [1] [5] In one study, CIN occurred in one-third of 439 consecutive patients who underwent PCI despite pre-procedure hydration and the use of non-ionic CM.[5]
Although baseline creatinine is not reliable enough for identification of patients at risk for CIN, this is because serum creatinine value varies with age, muscle mass, and gender, one of the studies shown that the higher the baseline creatinine value, the greater is the risk of CIN.
- If baseline plasma creatinine level is less than or equal to 1.2 mg/dl, the risk of CIN is only 2%
- Values of creatinine in the range of 1.4–1.9 mg/dl, the risk of CIN compared with that in the previous group increases fivefold (10.4%)
- Patients with baseline creatinine level more than 2.0 mg/dl, more than half of them (62%) subsequently develop CIN.[6]
Diabetes Mellitus
Due to high prevalence of diabetes in the general population, and the ability of the disease to cause a broad spectrum of cardiovascular diseases that require radiological procedures using CM, diabetic patients represent a significant proportion of those undergoing contrast exposure with incidence of CIN varies from 5.7 to 29.4%.[7] The rates of CIN are usually comparable to those of a non-diabetic population in diabetics patients with preserved renal function.[8]
Diabetes mellitus with associated renal insufficiency has been identified as an independent risk factor for contrast nephropathy, with as many as 56% of those who develop the condition progressing to irreversible renal failure. In addition, diabetic patients who have advanced chronic renal failure (serum creatinine levels > 3.5 mg/dL) due to causes other than diabetic nephropathy are significantly at higher risk of developing CIN.[9]
Age
The reasons for high risk to develop CIN in elderly were not studied specifically and probably are multifactorial, including age-related changes in renal function (diminished glomerular filtration rate, tubular secretion, and concentrating ability). Several studies proved that older age is an independent predictor of CIN.[10] [11]
Volume of Contrast Media
The correlation between the amount of CM and the risk of CIN is well documented,[1] [11] [12] [13] [14] [15] Most of the studies indicate that the higher volume of CM have a great damaging effect in the presence of other risk factors, even relatively low doses of contrast (less than 100 ml) can induce permanent renal failure and the need for dialysis in patients with chronic kidney disease.
Previous contrast media administration
Multiple injections of contrast media within 72 hour increase the risk of the patient's developing contrast-induced nephropathy.[16] [17] [18]
Osmolarity of the contrast media
Large clinical studies and meta-analyses indicated that the use of an low osmolarity CM reduces the risk of nephropathy in high-risk patients compared with the use of High osmolarity CM.[19] [20]
Anemia might be one of the factors contributing to renal ischemia, in a study based on interventional cardiology database analysis, it showed a steadily increased rates of CIN as pre-procedure hematocrit decreased.[21]
Reduction of Effective Intravascular Volume
Reduction of effective intravascular volume can lead to reduction in renal perfusion, thus enhancing the ischemic insult of contrast media. Congestive heart failure, liver cirrhosis, abnormal fluid losses, dehydration, and prolonged hypotension (especially when induced by intensive antihypertensive treatment combined with angiotensin-converting enzyme inhibitors and diuretics), all of which contribute to reduce the intravascular volume.[22] [23] [24] [17]
Nephrotoxic Drugs
Some drugs have been reported to render the kidney more vulnerable to the nephrotoxic effect of the contrast, directly nephrotoxic drugs (e.g., cyclosporin A, aminoglycosides, amphotericin, and cisplatin) and those that inhibit the local vasodilatory effects of prostaglandins (e.g., nonsteroidal antiinflammatory drugs NSAIDs)[25]
Others
Sepsis has been reported as being a risk factor through direct damage by bacterial toxins to renal tubules. Hypertension, multiple myeloma, peripheral vascular disease, and atopic allergy also have been reported as risk factors.[26] [16]
2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury
Assessment of the population at risk for CI-AKI
| Not Graded |
| "1. Assess the risk for CI-AKI and, in particular, screen for pre-existing impairment of kidney function in all patients who are considered for a procedure that requires intravascular (i.v. or i.a.) administration of iodinated contrast medium. (Level of Evidence: Not Graded)" |
| "2. Consider alternative imaging methods in patients at increased risk for CI-AKI. (Level of Evidence: Not Graded)" |
References
- ↑ 1.0 1.1 1.2 McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW (1997). "Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality". Am J Med. 103 (5): 368–75. PMID 9375704.
- ↑ Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, Legako RD, Leon DF, Murray JA, Nissen SE, Pepine CJ, Watson RM, Ritchie JL, Gibbons RJ, Cheitlin MD, Gardner TJ, Garson A Jr, Russell RO Jr, Ryan TJ, Smith SC Jr (1999). "ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions". J Am Coll Cardiol. 33 (6): 1756–824. PMID 10334456.
- ↑ Mehran R, Aymong ED, Nikolsky E; et al. (2004). "A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation". J. Am. Coll. Cardiol. 44 (7): 1393–9. doi:10.1016/j.jacc.2004.06.068. PMID 15464318.
- ↑ Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ; et al. (2002). "Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention". Circulation. 105 (19): 2259–64. PMID 12010907.
- ↑ 5.0 5.1 Gruberg L, Mehran R, Dangas G, Mintz GS, Waksman R, Kent KM; et al. (2001). "Acute renal failure requiring dialysis after percutaneous coronary interventions". Catheter Cardiovasc Interv. 52 (4): 409–16. doi:10.1002/ccd.1093. PMID 11285590.
- ↑ Hall KA, Wong RW, Hunter GC, Camazine BM, Rappaport WA, Smyth SH; et al. (1992). "Contrast-induced nephrotoxicity: the effects of vasodilator therapy". J Surg Res. 53 (4): 317–20. PMID 1405611.
- ↑ Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z; et al. (2004). "Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention". Am J Cardiol. 94 (3): 300–5. doi:10.1016/j.amjcard.2004.04.023. PMID 15276092.
- ↑ Lasser EC, Lyon SG, Berry CC (1997). "Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration". Radiology. 203 (3): 605–10. PMID 9169676.
- ↑ Manske CL, Sprafka JM, Strony JT, Wang Y (1990). "Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography". Am J Med. 89 (5): 615–20. PMID 2239981.
- ↑ Gussenhoven MJ, Ravensbergen J, van Bockel JH, Feuth JD, Aarts JC (1991). "Renal dysfunction after angiography; a risk factor analysis in patients with peripheral vascular disease". J Cardiovasc Surg (Torino). 32 (1): 81–6. PMID 2010458.
- ↑ 11.0 11.1 Kini AS, Mitre CA, Kim M, Kamran M, Reich D, Sharma SK (2002). "A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam". Catheter Cardiovasc Interv. 55 (2): 169–73. PMID 11835641.
- ↑ Diaz-Sandoval LJ, Kosowsky BD, Losordo DW (2002). "Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial)". Am J Cardiol. 89 (3): 356–8. PMID 11809444.
- ↑ Albert SG, Shapiro MJ, Brown WW, Goodgold H, Zuckerman D, Durham R; et al. (1994). "Analysis of radiocontrast-induced nephropathy by dual-labeled radionuclide clearance". Invest Radiol. 29 (6): 618–23. PMID 8088970.
- ↑ Rosovsky MA, Rusinek H, Berenstein A, Basak S, Setton A, Nelson PK (1996). "High-dose administration of nonionic contrast media: a retrospective review". Radiology. 200 (1): 119–22. PMID 8657898.
- ↑ Kahn JK, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Shimshak TM; et al. (1990). "High-dose contrast agent administration during complex coronary angioplasty". Am Heart J. 120 (3): 533–6. PMID 2389689.
- ↑ 16.0 16.1 Cochran ST, Wong WS, Roe DJ (1983). "Predicting angiography-induced acute renal function impairment: clinical risk model". AJR Am J Roentgenol. 141 (5): 1027–33. doi:10.2214/ajr.141.5.1027. PMID 6605043.
- ↑ 17.0 17.1 Byrd L, Sherman RL (1979). "Radiocontrast-induced acute renal failure: a clinical and pathophysiologic review". Medicine (Baltimore). 58 (3): 270–9. PMID 449662.
- ↑ Oliveira DB (1999). "Prophylaxis against contrast-induced nephropathy". Lancet. 353 (9165): 1638–9. doi:10.1016/S0140-6736(98)90076-9. PMID 10335780.
- ↑ Taliercio CP, Vlietstra RE, Ilstrup DM, Burnett JC, Menke KK, Stensrud SL; et al. (1991). "A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography". J Am Coll Cardiol. 17 (2): 384–90. PMID 1991894.
- ↑ Barrett BJ, Carlisle EJ (1993). "Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media". Radiology. 188 (1): 171–8. PMID 8511292.
- ↑ Nikolsky E, Mehran R, Lasic Z, Mintz GS, Lansky AJ, Na Y; et al. (2005). "Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions". Kidney Int. 67 (2): 706–13. doi:10.1111/j.1523-1755.2005.67131.x. PMID 15673320.
- ↑ Barrett BJ, Parfrey PS (1994). "Prevention of nephrotoxicity induced by radiocontrast agents". N Engl J Med. 331 (21): 1449–50. doi:10.1056/NEJM199411243312111. PMID 7969286.
- ↑ Rudnick MR, Berns JS, Cohen RM, Goldfarb S (1994). "Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism--a critical review". Am J Kidney Dis. 24 (4): 713–27. PMID 7942832.
- ↑ Lang EK, Foreman J, Schlegel JU, Leslie C, List A, McCormick P (1981). "The incidence of contrast medium induced acute tubular necrosis following arteriography". Radiology. 138 (1): 203–6. PMID 7455084.
- ↑ Morcos SK (1998). "Contrast media-induced nephrotoxicity--questions and answers". Br J Radiol. 71 (844): 357–65. PMID 9659127.
- ↑ Kolonko A, Kokot F, Wiecek A (1998). "Contrast-associated nephropathy--old clinical problem and new therapeutic perspectives". Nephrol Dial Transplant. 13 (3): 803–6. PMID 9550679.